Form 4: Incyte Corp EVP Barry Flannelly Reports Stock Transactions
SEC Form 4 Filing
EVP & General Manager US of Incyte Corp, Barry P Flannelly, reports acquisition and disposal of common stock on November 6, 2024, according to a Form 4 filing with the SEC.
Summary
- Barry P Flannelly, EVP & General Manager US of Incyte Corp, filed a Form 4 with the SEC on November 8, 2024.
- The report details transactions involving Incyte Corp common stock on November 6, 2024.
- Flannelly acquired 1,424 shares at $72.27 and 2,256 shares at $68.62 through the exercise of employee stock options.
- He also disposed of 1,424 shares at $82 and 2,256 shares at $78.21.
- Following these transactions, Flannelly beneficially owns 58,042 shares of Incyte Corp common stock, including unvested RSUs and earned performance shares.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive, indicating a neutral sentiment.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Executive stock option exercises and sales are typical compensation components in the pharmaceutical industry, used by companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals.
- The vesting schedules and terms of the options granted to Barry Flannelly appear consistent with standard practices for executive compensation in similar-sized biotech firms.
- Comparing the transaction prices with Incyte's historical stock performance can provide context on whether these transactions were opportunistic or part of a pre-planned strategy, similar to how investors analyze insider trading activity at companies like Regeneron or Biogen.
Stakeholder Impact
- The stock transactions may influence investor sentiment, although individual transactions by executives don't always have a significant impact.
- Employees holding company stock or options may be interested in the transaction prices and potential implications for their own holdings.
Key Dates
| Date | Description |
|---|---|
| 2018-07-02 | Options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years. |
| 2019-01-04 | Options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years. |
| 2019-07-02 | First 25% of options vest. |
| 2024-08-02 | Power of Attorney executed. |
| 2024-11-06 | Date of stock transactions (acquisition and disposal). |
| 2024-11-08 | Date of Form 4 filing. |
| 2028-07-01 | Expiration date of Employee Stock Option. |
| 2029-01-03 | Expiration date of Employee Stock Option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.